Non-alcoholic fatty liver disease. Other specified inflammatory liver diseases
Conditions
Interventions
Intervention 1: Intervention group: In the intervention group, flaxseed oil capsules made by Barij Essense Company is prescribed in a dose of 1g 2 times a day for 2 months (one capsule two times a da
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patient satisfaction AST and ALT level at least 1/5 times normal with ultrasound confirmation of fatty liver Age: 15 to 60
Exclusion criteria
Exclusion criteria: Consumption or history of alcohol consumption Positive serology of viral hepatitis (C, B) ANA or AMA, alpha 1 antitrypsin positive test, low serum ceruloplasin level or high level of ASMA and LKM14 antibodies Ferritin above 450 or 45% IRON / TIBC> 5 The patient develops an acute or chronic illness before or during the intervention that interferes with LFT (liver function tests) The patient take a drug before or during the intervention that has the potential to interfere with LFT Age less than 15 years and more than 60 years Pregnancy Taking herbal medicine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AST level changes. Timepoint: AST level measurement at baseline and at week 8. Method of measurement: blood sample.;ALT level changes. Timepoint: ALT level measurement at baseline and at week 8. Method of measurement: blood sample.;ALP level changes. Timepoint: ALP level measurement at baseline and at week 8. Method of measurement: blood sample.;Bilirubin total and direct level changes. Timepoint: Bilirubin total and direct level measurement at baseline and at week 8. Method of measurement: blood sample. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting Blood Sugar. Timepoint: at baseline and at week 8. Method of measurement: blood sample.;Weight. Timepoint: at baseline and at week 8. Method of measurement: Weighing scale.;Height. Timepoint: at baseline and at week 8. Method of measurement: Meter.;High-density lipoprotein (HDL). Timepoint: at baseline and at week 8. Method of measurement: Blood sample.;Low-density lipoprotein (LDL). Timepoint: at baseline and at week 8. Method of measurement: Blood sample.;Cholesterol. Timepoint: at baseline and at week 8. Method of measurement: Blood sample.;Triglyceride. Timepoint: at baseline and at week 8. Method of measurement: Blood sample.;Body mass index (BMI). Timepoint: at baseline and at week 8. Method of measurement: Body weight (kg) divided by the square of the body height(m). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDelaram Omidvar
Mashhad University of Medical Sciences
Outcome results
None listed